Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
Open Access
- 15 October 2013
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 36 (11) , 3517-3525
Abstract
OBJECTIVE: To add to the evidence on comparative long-term effects of insulin analog glargine versus human NPH insulin on the risk for cancer. RESEARCH DESIGN AND METHODS: We identified cohorts of initiators of glargine and human NPH without an insulin prescription during the prior 19 months among patients covered by the Inovalon Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry) between January 2003 and December 2010. Patients were required to have a second prescription of the same insulin within 180 days and to be free of cancer. We balanced cohorts on risk factors for cancer outcomes based on comorbidities, comedication, and health care use during the prior 12 months using inverse probability of treatment weighting. Incident cancer was defined as having two claims for cancer (any cancer) or the same cancer (breast, prostate, colon) within 2 months. We estimated adjusted hazard ratios (HRs) and their 95% CI using weighted Cox models censoring for stopping, switching, or augmenting insulin treatment, end of enrollment, and mortality. RESULTS: More patients initiated glargine (43,306) than NPH (9,147). Initiators of glargine (NPH) were followed for 1.2 (1.1) years and 50,548 (10,011) person-years; 993 (178) developed cancer. The overall HR was 1.12 (95% CI 0.95–1.32). Results were consistent for breast cancer, prostate cancer, and colon cancer; various durations of treatment; and sensitivity analyses. CONCLUSIONS: Patients initiating insulin glargine rather than NPH do not seem to be at an increased risk for cancer. While our study contributes significantly to our evidence base for long-term effects, this evidence is very limited mainly based on actual dynamics in insulin prescribing.Keywords
This publication has 33 references indexed in Scilit:
- Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance DatabaseDiabetologia, 2012
- Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up studyDiabetologia, 2011
- Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation StudyAmerican Journal of Epidemiology, 2010
- Combined randomised controlled trial experience of malignancies in studies using insulin glargineDiabetologia, 2009
- Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label studyDiabetologia, 2009
- Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia, 2009
- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia, 2009
- Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External InformationMedical Care, 2007
- Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry dataCancer Causes & Control, 2007
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983